{"hands_on_practices": [{"introduction": "Managing severe pain is a cornerstone of palliative care, and opioid rotation is a critical skill when a patient's pain is poorly controlled or they experience intolerable side effects. This practice requires careful quantitative reasoning to convert from one opioid to another while maintaining safety and analgesia. In this exercise [@problem_id:4974619], you will work through a common clinical scenario of converting a patient from oral morphine to a transdermal fentanyl patch due to difficulty swallowing, applying the principles of equianalgesia and dose reduction for incomplete cross-tolerance.", "problem": "A 70-year-old patient with metastatic pancreatic adenocarcinoma has maintained stable pain control for the past week on oral morphine. The regimen consists of extended-release morphine (ERM) 80 mg every 12 hours, and immediate-release morphine 10 mg taken on average three times per day for breakthrough pain. Due to progressive dysphagia, the care team plans to switch to transdermal fentanyl. Use the equianalgesic principle, which states that two distinct analgesic regimens can be considered equianalgesic when they yield comparable analgesia under stable clinical conditions, and use well-tested clinical reference points that approximate the conversion between total daily oral morphine and transdermal fentanyl delivery rate at steady state.\n\nAssume the following anchor points from published equianalgesic tables apply to a clinically stable adult without severe organ dysfunction:\n- $25~\\mu\\text{g}/\\text{h}$ transdermal fentanyl $\\sim 60~\\text{mg/day}$ oral morphine,\n- $50~\\mu\\text{g}/\\text{h}$ transdermal fentanyl $\\sim 120~\\text{mg/day}$ oral morphine,\n- $75~\\mu\\text{g}/\\text{h}$ transdermal fentanyl $\\sim 180~\\text{mg/day}$ oral morphine,\n- $100~\\mu\\text{g}/\\text{h}$ transdermal fentanyl $\\sim 240~\\text{mg/day}$ oral morphine.\n\nStarting from these anchors, derive a conversion that maps the patientâ€™s 24-hour oral morphine total to an equivalent steady transdermal fentanyl delivery rate. Then, adjust for incomplete cross-tolerance by applying a reduction factor of $40\\%$ to the calculated fentanyl rate before recommending an initial transdermal fentanyl delivery rate. Express the final answer in micrograms per hour ($\\mu\\text{g}/\\text{h}$) and round your answer to three significant figures. Do not adjust to commercially available patch sizes; report the continuous value you derive.", "solution": "The problem requires the calculation of an initial transdermal fentanyl delivery rate for a patient being converted from an oral morphine regimen. The solution must be derived by first validating the problem statement for scientific soundness, consistency, and completeness.\n\n### Step 1: Extract Givens\nThe data and conditions provided in the problem statement are as follows:\n- Patient: $70$-year-old with metastatic pancreatic adenocarcinoma.\n- Current pain control: Stable for the past week.\n- Current regimen (oral morphine):\n    - Extended-release morphine (ERM): $80 \\text{ mg}$ every $12$ hours.\n    - Immediate-release morphine (IRM): $10 \\text{ mg}$ taken on average three times per day for breakthrough pain.\n- Reason for conversion: Progressive dysphagia.\n- Target medication: Transdermal fentanyl.\n- Conversion principle: Equianalgesic principle.\n- Equianalgesic anchor points (oral morphine dose per day vs. transdermal fentanyl delivery rate):\n    - $25~\\mu\\text{g}/\\text{h}$ fentanyl $\\sim 60~\\text{mg/day}$ morphine.\n    - $50~\\mu\\text{g}/\\text{h}$ fentanyl $\\sim 120~\\text{mg/day}$ morphine.\n    - $75~\\mu\\text{g}/\\text{h}$ fentanyl $\\sim 180~\\text{mg/day}$ morphine.\n    - $100~\\mu\\text{g}/\\text{h}$ fentanyl $\\sim 240~\\text{mg/day}$ morphine.\n- Adjustment for incomplete cross-tolerance: A reduction factor of $40\\%$ applied to the calculated fentanyl rate.\n- Required final answer format: Continuous value in micrograms per hour ($\\mu\\text{g}/\\text{h}$), rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the required criteria.\n\n- **Scientifically Grounded**: The problem is set in a clinical context (palliative medicine) and uses established pharmacological principles, namely equianalgesia and adjustment for incomplete cross-tolerance when switching between opioids. The provided conversion ratios are consistent with those found in clinical guidelines, representing a simplified but standard model for opioid rotation. The scenario is a common and realistic clinical challenge. The problem is scientifically sound.\n- **Well-Posed**: All necessary information is provided. The patient's total daily dose of morphine can be calculated, a conversion relationship can be derived from the anchor points, and a specific reduction factor is given. The objective is clearly stated, leading to a unique solution.\n- **Objective**: The problem uses precise, objective clinical language and quantitative data. There are no subjective or ambiguous statements.\n\nThe problem does not exhibit any of the flaws listed for invalidation. It is scientifically grounded, well-posed, and objective. It is a formalizable problem directly relevant to the specified topic.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. The solution process will now proceed.\n\n### Solution Derivation\n\nThe process involves three main steps: 1) calculating the total daily dose (TDD) of oral morphine, 2) determining the equianalgesic transdermal fentanyl rate based on the provided conversion model, and 3) applying the specified dose reduction for incomplete cross-tolerance.\n\n**1. Calculate the Total Daily Dose (TDD) of Oral Morphine**\n\nThe patient's TDD is the sum of the scheduled extended-release dose and the average dose for breakthrough pain.\nLet $M_{TDD}$ be the total daily dose of oral morphine in $\\text{mg}$.\nThe dose from extended-release morphine ($M_{ER}$) is $80 \\text{ mg}$ administered every $12$ hours, which corresponds to $2$ doses per $24$-hour period.\n$$M_{ER} = 80 \\frac{\\text{mg}}{\\text{dose}} \\times 2 \\frac{\\text{doses}}{\\text{day}} = 160 \\frac{\\text{mg}}{\\text{day}}$$\nThe dose from immediate-release morphine ($M_{IR}$) for breakthrough pain is $10 \\text{ mg}$ taken an average of $3$ times per day.\n$$M_{IR} = 10 \\frac{\\text{mg}}{\\text{dose}} \\times 3 \\frac{\\text{doses}}{\\text{day}} = 30 \\frac{\\text{mg}}{\\text{day}}$$\nThe total daily dose of oral morphine is the sum of these two components.\n$$M_{TDD} = M_{ER} + M_{IR} = 160 \\frac{\\text{mg}}{\\text{day}} + 30 \\frac{\\text{mg}}{\\text{day}} = 190 \\frac{\\text{mg}}{\\text{day}}$$\n\n**2. Determine the Equianalgesic Fentanyl Rate**\n\nLet $F$ be the transdermal fentanyl delivery rate in $\\mu\\text{g}/\\text{h}$ and $M$ be the total daily oral morphine dose in $\\text{mg/day}$. We must establish the mathematical relationship between $F$ and $M$ using the provided anchor points. Let's examine the ratio $R = M/F$ for each point.\n$$R_1 = \\frac{60}{25} = 2.4$$\n$$R_2 = \\frac{120}{50} = 2.4$$\n$$R_3 = \\frac{180}{75} = 2.4$$\n$$R_4 = \\frac{240}{100} = 2.4$$\nThe ratio is constant across all anchor points, confirming a linear relationship of the form $M = R \\cdot F$, where the conversion constant $R = 2.4 \\frac{\\text{mg/day}}{\\mu\\text{g/h}}$. This relationship can be rearranged to solve for the fentanyl rate:\n$$F = \\frac{M}{R} = \\frac{M}{2.4}$$\nNow, we can calculate the equianalgesic fentanyl rate, $F_{eq}$, corresponding to the patient's $M_{TDD}$ of $190 \\text{ mg/day}$.\n$$F_{eq} = \\frac{190}{2.4} \\frac{\\mu\\text{g}}{\\text{h}} \\approx 79.166... \\frac{\\mu\\text{g}}{\\text{h}}$$\n\n**3. Adjust for Incomplete Cross-Tolerance and Finalize the Dose**\n\nWhen rotating between different opioids, a dose reduction is standard practice to account for incomplete cross-tolerance, which mitigates the risk of overdose. The problem specifies a reduction factor of $40\\%$. Therefore, the initial recommended dose, $F_{initial}$, should be $100\\% - 40\\% = 60\\%$ of the calculated equianalgesic dose.\nLet the reduction factor be $f_{red} = 0.40$. The final dose is calculated as:\n$$F_{initial} = F_{eq} \\times (1 - f_{red})$$\n$$F_{initial} = \\left(\\frac{190}{2.4}\\right) \\times (1 - 0.40) = \\left(\\frac{190}{2.4}\\right) \\times 0.60$$\n$$F_{initial} = \\frac{190 \\times 0.60}{2.4} = \\frac{114}{2.4} = 47.5 \\frac{\\mu\\text{g}}{\\text{h}}$$\nThe problem requires the final answer to be rounded to three significant figures. The calculated value of $47.5$ already has exactly three significant figures.\n\nTherefore, the recommended initial transdermal fentanyl delivery rate is $47.5~\\mu\\text{g}/\\text{h}$.", "answer": "$$\\boxed{47.5}$$", "id": "4974619"}, {"introduction": "Effective symptom management extends beyond treating the primary complaint; it involves proactively anticipating and managing the side effects of our interventions. Opioids are highly effective for pain but almost universally cause constipation, which can be a major source of distress for patients. This problem [@problem_id:4974456] provides a hands-on application of pharmacodynamic principles to construct a prophylactic bowel regimen, demonstrating how to quantitatively tailor laxative dosing to counteract the effects of opioids and achieve a specific clinical target.", "problem": "A patient with metastatic lung cancer is starting high-dose sustained-release oral morphine at a total morphine equivalent daily dose of $200$ mg for severe pain. The patient has no signs of bowel obstruction, normal renal function, and maintains adequate oral fluid intake. Two days prior to opioid initiation, the patient's typical stool corresponded to Bristol Stool Form Scale (BSFS) type $4$. The clinical goal is to maintain stool consistency near BSFS type $4$, which is assumed to correspond to a mean colonic transit time of $48$ hours.\n\nForty-eight hours after starting opioids, the mean colonic transit time estimated by radio-opaque marker study is $72$ hours, consistent with opioid-induced slowing of gut motility. As part of prophylaxis for opioid-induced constipation, the plan is to begin stimulant sennosides at a standard starting dose of $17.2$ mg at bedtime and to add daily oral Polyethylene Glycol (PEG $3350$) with a dose calculated to restore the mean colonic transit time toward the $48$-hour target.\n\nUse the following modeling assumptions for the pharmacodynamic effect of laxatives on mean colonic transit time:\n- For sennosides, the reduction in mean colonic transit time is saturable with a maximum achievable reduction of $12$ hours and a half-maximum (median effective dose) of $48$ mg.\n- For PEG $3350$, the reduction in mean colonic transit time is saturable with a maximum achievable reduction of $24$ hours and a half-maximum (median effective dose) of $34$ g.\n- For initial low-to-moderate dosing used in prophylaxis, the dose-response near zero dose may be approximated by the first-order (linear) term of a standard saturable model.\n\nConstruct a scientifically appropriate prophylactic bowel regimen by combining stimulant sennosides and PEG $3350$, and, based on the above assumptions, compute the single daily PEG $3350$ dose in grams required, when added to the fixed sennosides dose of $17.2$ mg, to reduce the opioid-affected mean colonic transit time from $72$ hours toward the $48$-hour target. Assume additive reductions in mean colonic transit time between sennosides and PEG $3350$ at these initial doses.\n\nExpress the final daily PEG $3350$ dose in grams, rounded to three significant figures.", "solution": "The objective is to calculate the daily dose of Polyethylene Glycol (PEG $3350$) required to restore a patient's mean colonic transit time (CTT) to a target value, given the effects of an opioid and a fixed-dose stimulant laxative.\n\nThe initial mean CTT, after starting morphine, is $T_{\\text{current}} = 72$ hours. The clinical target for the mean CTT is $T_{\\text{target}} = 48$ hours.\nThe total required reduction in mean CTT, denoted as $\\Delta T_{\\text{total}}$, is the difference between the current and target times:\n$$ \\Delta T_{\\text{total}} = T_{\\text{current}} - T_{\\text{target}} = 72 \\text{ hours} - 48 \\text{ hours} = 24 \\text{ hours} $$\nThe problem specifies that the pharmacodynamic effect of the laxatives (the reduction in CTT) can be described by a saturable model, often represented by the Michaelis-Menten or Hill equation form:\n$$ \\Delta T(D) = \\frac{E_{\\text{max}} \\cdot D}{ED_{50} + D} $$\nHere, $\\Delta T(D)$ is the reduction in CTT for a given dose $D$, $E_{\\text{max}}$ is the maximum achievable reduction, and $ED_{50}$ is the dose that produces half of the maximum effect.\n\nFor the prophylactic regimen, the problem instructs to use a first-order (linear) approximation of this model, which is valid for low-to-moderate doses. This approximation corresponds to the initial slope of the dose-response curve at $D=0$. The slope, or potency constant $k$, is the derivative of $\\Delta T(D)$ with respect to $D$, evaluated at $D=0$:\n$$ k = \\frac{d}{dD}\\left(\\frac{E_{\\text{max}} \\cdot D}{ED_{50} + D}\\right)\\bigg|_{D=0} = \\frac{E_{\\text{max}}(ED_{50} + D) - (E_{\\text{max}} \\cdot D)(1)}{(ED_{50} + D)^2}\\bigg|_{D=0} = \\frac{E_{\\text{max}}}{ED_{50}} $$\nThe linear approximation for the reduction in transit time is therefore:\n$$ \\Delta T(D) \\approx k \\cdot D = \\left(\\frac{E_{\\text{max}}}{ED_{50}}\\right) D $$\nWe are given two laxatives, sennosides (S) and PEG $3350$ (P), and their effects are assumed to be additive. The total reduction is the sum of the individual reductions:\n$$ \\Delta T_{\\text{total}} = \\Delta T_S + \\Delta T_P $$\nFirst, we calculate the reduction in CTT provided by the fixed dose of sennosides.\nThe parameters for sennosides are:\nDose, $D_S = 17.2$ mg.\nMaximum reduction, $E_{\\text{max},S} = 12$ hours.\nHalf-maximum dose, $ED_{50,S} = 48$ mg.\n\nThe potency constant for sennosides, $k_S$, is:\n$$ k_S = \\frac{E_{\\text{max},S}}{ED_{50,S}} = \\frac{12 \\text{ hours}}{48 \\text{ mg}} = 0.25 \\frac{\\text{hours}}{\\text{mg}} $$\nThe reduction in CTT from the sennosides dose is:\n$$ \\Delta T_S = k_S \\cdot D_S = \\left(0.25 \\frac{\\text{hours}}{\\text{mg}}\\right) \\cdot (17.2 \\text{ mg}) = 4.3 \\text{ hours} $$\nNow, we can determine the remaining reduction in CTT that must be achieved by PEG $3350$, $\\Delta T_P$:\n$$ \\Delta T_P = \\Delta T_{\\text{total}} - \\Delta T_S = 24 \\text{ hours} - 4.3 \\text{ hours} = 19.7 \\text{ hours} $$\nNext, we calculate the dose of PEG $3350$, $D_P$, required to produce this $19.7$-hour reduction.\nThe parameters for PEG $3350$ are:\nMaximum reduction, $E_{\\text{max},P} = 24$ hours.\nHalf-maximum dose, $ED_{50,P} = 34$ g.\n\nThe potency constant for PEG $3350$, $k_P$, is:\n$$ k_P = \\frac{E_{\\text{max},P}}{ED_{50,P}} = \\frac{24 \\text{ hours}}{34 \\text{ g}} = \\frac{12}{17} \\frac{\\text{hours}}{\\text{g}} $$\nUsing the linear model $\\Delta T_P = k_P \\cdot D_P$, we solve for the dose $D_P$:\n$$ D_P = \\frac{\\Delta T_P}{k_P} = \\frac{19.7 \\text{ hours}}{\\frac{12}{17} \\frac{\\text{hours}}{\\text{g}}} = 19.7 \\cdot \\frac{17}{12} \\text{ g} $$\nPerforming the final calculation:\n$$ D_P = \\frac{334.9}{12} \\text{ g} \\approx 27.90833... \\text{ g} $$\nThe problem requires the answer to be rounded to three significant figures.\n$$ D_P \\approx 27.9 \\text{ g} $$\nThis result is derived strictly following the modeling assumptions provided in the problem statement.", "answer": "$$\\boxed{27.9}$$", "id": "4974456"}, {"introduction": "Palliative medicine often requires navigating profound ethical questions about the goals of care, particularly when life-sustaining treatments may offer diminishing returns at the cost of significant patient burden. This thought experiment [@problem_id:4974342] introduces a structured framework for grappling with the concept of medical futility by applying a proportionality analysis. By quantifying expected benefits and harms using concepts like Quality-Adjusted Life-Years ($QALYs$), you can build a reasoned argument to help guide complex decisions and conversations at the end of life.", "problem": "A patient aged $76$ years with refractory septic shock, acute respiratory distress syndrome, and acute kidney injury requiring continuous renal replacement therapy is in multiorgan failure. The patient is already on high-dose norepinephrine, and the team is considering escalating vasopressor therapy by adding vasopressin and epinephrine. To assess whether escalation is proportionate or medically futile, use a proportionality analysis grounded in expected value and quality-adjusted life-year (QALY) concepts.\n\nUse the following ethically and clinically grounded assumptions, consistent with introductory decision analysis in medicine:\n\n- Quality-adjusted life-year (QALY) is defined as the integral of health-related quality of life over time; for a period with constant utility $u$ lasting duration $t$ (in years), this is $u \\times t$.\n- Expected value across uncertain outcomes is the probability-weighted sum of the values of those outcomes.\n\nBaseline (no escalation) trajectory:\n- Expected remaining time to death is $4$ days under comfort-focused care with an average utility of $0.6$.\n\nEscalation trajectory:\n- Let $p$ denote the probability that the patient survives to hospital discharge if vasopressors are escalated. If the patient survives to discharge, the expected post-discharge survival is $0.4$ years with a utility of $0.3$, preceded by an intensive care unit course of $14$ days with utility $0.1$. If the patient dies in the hospital despite escalation (probability $1-p$), the time to death is $10$ days with utility $0.1$.\n- Independent of survival, escalation carries a probability $c=0.25$ of clinically significant ischemic complication (for example, digital ischemia) with a burden equivalent to a $0.02$ QALY decrement.\n\nFor the purposes of proportionality analysis, treat the expected benefit $E[B]$ as the expected post-discharge QALYs under escalation (there is no post-discharge survival without escalation), and treat the expected harm $E[H]$ as the sum of:\n- the expected shortfall in in-hospital QALYs under escalation relative to baseline comfort-focused care, plus\n- the expected QALY-equivalent burden of ischemic complications.\n\nCompute the threshold probability $p^{\\ast}$ such that $E[B]=E[H]$. Report $p^{\\ast}$ as a decimal fraction rounded to three significant figures. Assume a $365$-day year for all day-to-year conversions and express the final number without any unit symbols.", "solution": "The problem statement is a valid application of decision analysis and bioethical principles to a realistic clinical scenario. It is scientifically grounded, well-posed, objective, and contains all necessary information to derive a unique solution. Therefore, the problem is valid, and we proceed with the analysis.\n\nThe goal is to find the threshold probability of survival to hospital discharge, denoted as $p^{\\ast}$, at which the expected benefit $E[B]$ of escalating vasopressor therapy equals its expected harm $E[H]$. We are given the condition $E[B] = E[H]$. We must first formulate expressions for $E[B]$ and $E[H]$ as functions of the probability $p$. For all calculations, time in days must be converted to years using the given conversion of $1 \\text{ year} = 365 \\text{ days}$.\n\nFirst, we calculate the expected benefit, $E[B]$, which is defined as the expected post-discharge Quality-Adjusted Life-Years (QALYs). This benefit is only realized if the patient survives to discharge, an event with probability $p$. The post-discharge survival is $t_{post} = 0.4$ years with a utility of $u_{post} = 0.3$. The QALYs for this period are the product of duration and utility.\n$$\nQALY_{post} = u_{post} \\times t_{post} = 0.3 \\times 0.4 = 0.12\n$$\nThe expected benefit is then the value of this outcome multiplied by its probability:\n$$\nE[B] = p \\times QALY_{post} = 0.12p\n$$\n\nNext, we calculate the expected harm, $E[H]$, which is the sum of two components: ($1$) the expected shortfall in in-hospital QALYs under escalation compared to baseline, and ($2$) the expected QALY-equivalent burden of ischemic complications.\n$$\nE[H] = E[\\text{QALY shortfall}] + E[\\text{complication burden}]\n$$\n\nLet's compute the first component of harm, the expected QALY shortfall. This requires calculating the QALYs for the baseline (no escalation) trajectory and subtracting the expected in-hospital QALYs for the escalation trajectory.\n\nThe QALYs for the baseline trajectory ($QALY_{base}$) are calculated from an expected survival of $t_{base} = 4$ days with a utility of $u_{base} = 0.6$.\n$$\nt_{base} = \\frac{4}{365} \\text{ years}\n$$\n$$\nQALY_{base} = u_{base} \\times t_{base} = 0.6 \\times \\frac{4}{365} = \\frac{2.4}{365}\n$$\n\nThe expected in-hospital QALYs under escalation, $E[QALY_{in-hosp}]$, depend on two mutually exclusive outcomes:\n1.  Survival to discharge (probability $p$): The patient spends $t_{icu,s} = 14$ days in the ICU with a utility of $u_{icu,s} = 0.1$. The QALYs for this branch are $0.1 \\times \\frac{14}{365} = \\frac{1.4}{365}$.\n2.  Death in the hospital (probability $1-p$): The patient survives for $t_{icu,d} = 10$ days with a utility of $u_{icu,d} = 0.1$. The QALYs for this branch are $0.1 \\times \\frac{10}{365} = \\frac{1.0}{365}$.\n\nThe expected in-hospital QALYs are the probability-weighted sum of these outcomes:\n$$\nE[QALY_{in-hosp}] = p \\times \\left(0.1 \\times \\frac{14}{365}\\right) + (1-p) \\times \\left(0.1 \\times \\frac{10}{365}\\right)\n$$\n$$\nE[QALY_{in-hosp}] = \\frac{1.4p}{365} + \\frac{1.0(1-p)}{365} = \\frac{1.4p + 1.0 - 1.0p}{365} = \\frac{0.4p + 1.0}{365}\n$$\nThe expected QALY shortfall is the difference between baseline QALYs and expected in-hospital QALYs under escalation:\n$$\nE[\\text{QALY shortfall}] = QALY_{base} - E[QALY_{in-hosp}] = \\frac{2.4}{365} - \\frac{0.4p + 1.0}{365} = \\frac{2.4 - 0.4p - 1.0}{365} = \\frac{1.4 - 0.4p}{365}\n$$\n\nNow, we compute the second component of harm, the expected QALY-equivalent burden of ischemic complications, $E[\\text{complication burden}]$. This harm occurs with probability $c = 0.25$ and carries a QALY decrement of $0.02$.\n$$\nE[\\text{complication burden}] = c \\times (\\text{QALY decrement}) = 0.25 \\times 0.02 = 0.005\n$$\n\nWe can now write the full expression for the total expected harm, $E[H]$:\n$$\nE[H] = \\frac{1.4 - 0.4p}{365} + 0.005\n$$\n\nThe proportionality threshold $p^{\\ast}$ is found by setting $E[B] = E[H]$ and solving for $p$.\n$$\n0.12p = \\frac{1.4 - 0.4p}{365} + 0.005\n$$\nTo solve for $p$, we first multiply the entire equation by $365$ to eliminate the fraction:\n$$\n365 \\times (0.12p) = 365 \\times \\left(\\frac{1.4 - 0.4p}{365}\\right) + 365 \\times (0.005)\n$$\n$$\n43.8p = (1.4 - 0.4p) + 1.825\n$$\n$$\n43.8p = 3.225 - 0.4p\n$$\nNext, we group all terms containing $p$ on one side of the equation:\n$$\n43.8p + 0.4p = 3.225\n$$\n$$\n44.2p = 3.225\n$$\nFinally, we solve for $p$:\n$$\np = p^{\\ast} = \\frac{3.225}{44.2} \\approx 0.0729638009...\n$$\nThe problem requires the answer to be reported as a decimal fraction rounded to three significant figures. The first three significant figures are $7$, $2$, and $9$. The fourth significant figure is $6$, which is greater than or equal to $5$, so we round up the third significant figure.\n$$\np^{\\ast} \\approx 0.0730\n$$\nThe trailing zero is a significant figure.", "answer": "$$\\boxed{0.0730}$$", "id": "4974342"}]}